December 8, 2025Blood

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis reveals relapse linked to age, obesity, and WBC levels in B-ALL, suggesting improved therapies are needed.

This research aims to identify risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-ALL treated with blinatumomab.
Retrospective study of patients with Philadelphia chromosome-negative B-ALL receiving frontline blinatumomab-based regimens.
Analyzed results from 239 patients treated between 2013 and 2025.
Employ both univariate and multivariate analyses to assess relapse risk factors.
Composite complete response achieved in 236 patients (99%).
Identified older age, obesity, and elevated WBC as key factors for increased relapse risk.
After relapse, median overall survival was only 8.6 months, with 2-year OS at 30%.

Arora et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark